<DOC>
	<DOCNO>NCT00082381</DOCNO>
	<brief_summary>This multicenter , comparator-controlled , open-label , randomize , two-arm , parallel trial compare effect exenatide twice daily insulin glargine glycemic control , measure hemoglobin A1c ( HbA1c ) .</brief_summary>
	<brief_title>Effect AC2993 Compared With Insulin Glargine Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Patients treat stable dose one follow least 3 month prior screen : 1 . 1500 2550 mg/day immediaterelease metformin ( 1500 2000 mg/day extendedrelease metformin ) least optimally effective dose sulfonylurea , 2. fixeddose sulfonylurea/metformin combination therapy sulfonylurea metformin requirement individual component . HbA1c 7.0 % 10.0 % , inclusive . History stable body weight ( vary &gt; 10 % least three month prior screen ) . Female patient breastfeed , female patient childbearing potential ( surgically sterilize menarche 1year postmenopause ) Patients investigator site personnel directly affiliate study , immediate family investigator site personnel directly affiliate study . Patients employ Lilly Amylin . Patients participate study previously study use AC2993 GLP1 analog . Patients participate interventional medical , surgical , pharmaceutical study within 30 day prior screen . This criterion include drug receive regulatory approval indication time study entry . Patients great three episode severe hypoglycemia within 6 month prior screen . Patients undergo therapy malignancy , basal cell squamous cell skin cancer . Patients cardiac disease Class III IV , accord New York Heart Association criterion . Patients know allergy hypersensitivity insulin glargine , AC2993 , excipients contain agent . Patients characteristic contraindicate metformin sulfonylurea use , accord productspecific label , opinion investigator . Patients history renal transplantation currently receive renal dialysis serum creatinine &gt; =1.5 mg/dL male &gt; =1.3 mg/dL female . Patients obvious clinical sign symptom liver disease , acute chronic hepatitis , alanine aminotransferase/serum glutamicpyruvic transaminase great three time upper limit reference range . Patients know hemoglobinopathy chronic anemia . Patients receive chronic ( lasting longer 2 week ) systemic glucocorticoid therapy ( exclude topical inhale preparation ) receive therapy within 2 week immediately prior screening . Patients used prescription drug promote weight loss within 3 month prior screen . Patients condition ( include know drug alcohol abuse psychiatric disorder ) preclude follow complete protocol , opinion investigator . Patients fail satisfy investigator suitability participate reason .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Insulin glargine</keyword>
	<keyword>comparator</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>